# USANA Health Sciences share price today (USANA Health Sciences, Inc., USNA)

> USANA Health Sciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. USNA · Consumer Staples · Packaged Foods · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/usna

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $14.87 (−29.7% in a year)
- P/E: 47.3×, over 1 year
- Revenue (Jul 2026): $223 M (−5.3% on a year ago)
- Profit (Jul 2026): −$21.4 M (−321.5% on a year ago)
- Operating margin: 4.1% (−3.0 points on a year ago)
- ROE: 2%, FY26
- ROIC: 9.8%, against a 8.0% cost of capital: +1.8 points

The main question: the share price moved −29.7% in a year while yearly earnings per share moved −73.5%. The difference came from the market paying a higher multiple. ## What is the USANA Health Sciences share price today? USANA Health Sciences, Inc.'s share price was $14.87 at the close on 3 November 2026. That is 17.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between $13 and $23, and at that close it sat 16% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 14 weeks running. Over the last 1 year the share price moved −55% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does USANA Health Sciences pay? USANA Health Sciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is USANA Health Sciences on? USANA Health Sciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is USANA Health Sciences profitable? USANA Health Sciences, Inc. posted a net loss of $21.4 M in the Jul 2026 quarter. Full-year FY26 profit was $10.8 M. Over 4 years profit has grown −44.9% a year on average. That loss is 9.6% of the quarter's revenue. The same quarter a year earlier earned $9.7 M. 3 of the last 12 reported quarters were loss-making. Jul 2026 profit was −$21.4 M, −321.5% on a year earlier. For the full year, FY26 profit was $10.8 M (−74.4% on the year before). Why profit moved: revenue changed −5.3% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −167.7% and revenue +0.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does USANA Health Sciences make, and is it growing? USANA Health Sciences, Inc. reported $223 M of revenue in the Jul 2026 quarter, −5.3% on the same quarter a year earlier. Over 4 years it has grown −6.0% a year on average. The last full year, FY26, came in at $925 M. The last four reported quarters add to $913 M. FY26 revenue was $925 M, +8.3% on the year before. Recent pace: the last four quarters grew +0.6% on average, against −6.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1.6%, against +2.2% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does USANA Health Sciences keep? USANA Health Sciences, Inc.'s operating margin was 4.1% in the Jul 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Across 5 years it has been between 5.5% and 14.3%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −3.0 percentage points on the year while gross margin changed −0.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is USANA Health Sciences' profit turning into cash? Over the last 3 years, 132% of USANA Health Sciences, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $22.3 M of operating cash against $10.8 M of profit. After $13.8 M of spending on assets, $8.5 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does USANA Health Sciences' cash go? USANA Health Sciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $38.4 M on assets over the last 3 years. Averaged over those years that is 1.4% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $38.4 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is USANA Health Sciences' P/E ratio, and how does it compare with its own history? USANA Health Sciences, Inc.'s P/E is 47.3×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −73.5% while the price moved −29.7%. The price did better than earnings, which pushed the multiple up within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the USANA Health Sciences business getting better or worse? USANA Health Sciences, Inc.'s business is getting worse. Profit and EPS growth are shrinking: profit growth is −165.0% in the latest quarter, against −5.1% at its best in 12 quarters, with ROCE steady at 6.9%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does USANA Health Sciences earn on its capital? USANA Health Sciences, Inc. earned a ROE of 2% in FY26. Its return on capital used (ROIC) is 1.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 1.2% net margin and 1.25× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 1.2% net margin × 1.25× asset turnover × 1.27× leverage (assets divided by equity) ≈ 1.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 9.8% − 8.0% = +1.8 percentage points. The 8.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 9.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 3.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does USANA Health Sciences have too much debt? USANA Health Sciences, Inc. has total debt of $14.0 M against shareholder equity of $595 M as of Apr 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.05 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the USANA Health Sciences shareholding pattern? 7.8% of USANA Health Sciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is USANA Health Sciences from balance-sheet trouble? For USANA Health Sciences, Inc., the Z-score is 4.58. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.58 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does USANA Health Sciences rank in its industry? There is no score against its industry: USANA Health Sciences, Inc. is not among the largest members shown in this industry comparison for Packaged Foods. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is USANA Health Sciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to USANA Health Sciences in size? USANA Health Sciences is the 34th largest of 39 Packaged Foods companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Once Upon A Farm, PBC, Lifeway Foods, Inc. and CN Healthy Food Tech Group Corp. Just below it: Prenetics Global, Oatly Group AB and BRC Inc. ### Packaged Foods companies close in size

1. [Once Upon A Farm, PBC](https://www.sectoralpha.in/us/stocks/ofrm) $400 million
2. [Lifeway Foods, Inc.](https://www.sectoralpha.in/us/stocks/lway) $336 million
3. [CN Healthy Food Tech Group Corp.](https://www.sectoralpha.in/us/stocks/ucfi) $288 million
4. USANA Health Sciences, Inc. $275 million
5. [Prenetics Global Limited](https://www.sectoralpha.in/us/stocks/pre) $274 million
6. [Oatly Group AB](https://www.sectoralpha.in/us/stocks/otly) $253 million
7. [BRC Inc.](https://www.sectoralpha.in/us/stocks/brcc) $244 million

[All 39 Packaged Foods companies, largest first](https://www.sectoralpha.in/us/sectors/packaged-foods#all-companies)

### Companies close in size in other industries

1. [Matrix Service Company](https://www.sectoralpha.in/us/stocks/mtrx) $265 million · Engineering & Construction
2. [NACCO Industries, Inc.](https://www.sectoralpha.in/us/stocks/nc) $264 million · Thermal Coal
3. USANA Health Sciences, Inc. $264 million
4. [Perma-Fix Environmental Services, Inc.](https://www.sectoralpha.in/us/stocks/pesi) $264 million · Waste Management
5. [Electrovaya Inc.](https://www.sectoralpha.in/us/stocks/elva) $262 million · Electrical Equipment & Parts

## What else do people ask about USANA Health Sciences? ### What were USANA Health Sciences's latest quarterly results? USANA Health Sciences, Inc. reported revenue of $223 M and a net loss of $21.4 M for the Jul 2026 quarter. Revenue fell 5.3% and profit fell 321.5% compared with a year earlier. Earnings per share were −$1.16 (as of 3 November 2026). ### What is USANA Health Sciences's market cap? USANA Health Sciences, Inc.'s market capitalisation is $275 M at a stock price of $14.87. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is USANA Health Sciences performing? USANA Health Sciences, Inc.'s latest readings are below. In its latest quarter, revenue fell 5.3% and profit fell 321.5% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 14 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will USANA Health Sciences's stock price go up? This page does not forecast USANA Health Sciences, Inc.'s stock price. What it shows instead: the stock price is $14.87. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is USANA Health Sciences in its business cycle? USANA Health Sciences, Inc.'s FY26 operating margin was 5.5%, against a 5-year range of 5.5% to 14.3%: the low end of its own range, which is often where recoveries start. The latest quarter was 4.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the USANA Health Sciences story? The main question: the share price moved −29.7% in a year while yearly earnings per share moved −73.5%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is USANA Health Sciences a stock worth studying right now? What the numbers show: USANA Health Sciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.